Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00829777 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Intravenous 6β-Naltrexol (AIKO-150) in Opioid-Dependent Subjects
A Phase 1 study, sponsored by California Pacific Medical Center Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT00829777 is a Phase 1 study that has completed, run by California Pacific Medical Center Research Institute. The registered enrollment target is 8 participants.
The verdict
NCT00829777, a Phase 1 study, has completed, sponsored by California Pacific Medical Center Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of intravenous 6β-Naltrexol administered to opiate dependent subjects
Interventions
- DRUG 6β-Naltrexol escalating doses from 0.05-0.5 mg IV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2009-03 |
| Est. Completion | 2009-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00829777
The ClinicalTrials.gov registry entry for NCT00829777 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is California Pacific Medical Center Research Institute, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 6β-Naltrexol escalating doses from 0.05-0.5 mg IV is the first listed.
NCT00829777 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00829777 about?
NCT00829777 is a clinical study titled "Safety Study of Intravenous 6β-Naltrexol (AIKO-150) in Opioid-Dependent Subjects". The purpose of this study is to evaluate the safety and efficacy of intravenous 6β-Naltrexol administered to opiate dependent subjects
What is the current status of trial NCT00829777?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2009-03. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00829777?
The interventions under investigation include: 6β-Naltrexol escalating doses from 0.05-0.5 mg IV (DRUG).
Who is sponsoring clinical trial NCT00829777?
This trial is sponsored by California Pacific Medical Center Research Institute, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.